However, some people do not initially achieve this glycemic target with basal insulin plus oral therapy, and others experience later deterioration of control (6– 9).
For the 39% of completers not initially achieving target, adding insulin detemir provided clinically relevant further reductions of mean A1C from 7.6 to 7.1%.
The United Kingdom Prospective Diabetes Study (UKPDS 49), demonstrated that long-term monotherapy with either insulin, sulfonylureas, or metformin could not sustain the glycemic control initially achieved (HbA1c <7%).
But if eradication does not occur, this stronger selection can lead to increased rates of adaptation, effectively undoing any progress initially achieved.
Loss of donor chimerism after initially achieving full donor chimerism was not observed in any cohort.
A similar pattern emerged in patients initially not achieving PASI 50 in an open-label study (Kreuger et al. 2006).
The gestational age-adjusted birth weight variable did not initially meet all the assumptions of linear regression; therefore, it was log transformed to achieve normality.
Among those not initially on statins at baseline, however, the magnitude of AAC progression in those with subsequent frequent statin use was large enough to achieve statistical significance.
